Biodesix (BDSX) Q2 2023: Core Lung Diagnostics Revenue Surges 58% as Test Volumes Hit Record Highs

August 7, 2023 | By EarningsIQ Research

Biodesix’s core lung diagnostics business delivered a 58% revenue jump and 75% test volume growth, marking a pivotal operational inflection. Gross margin expansion and disciplined cost management accelerated the path toward profitability, with insider-led capital raising reinforcing leadership confidence. Momentum in clinical adoption and payer coverage sets the stage for continued growth, but biopharma services remain a drag amid industry-wide trial delays.

Summary

• Test Volume Inflection: Core lung diagnostics test volumes soared, driving operational leverage and market penetration.
• Margin Expansion Sustained: Gross margin improvement outpaced expectations, supporting a clearer path to profitability.
• Biopharma Services Remain Lumpy: Clinical trial delays continue to constrain non-core growth, though backlog signals latent demand.

Business Overview

Biodesix is a precision diagnostics company focused on lung disease, generating revenue primarily from blood-based lung cancer tests and biopharmaceutical services. Its core business centers on a portfolio of five Medicare-covered lung diagnostics, including Notify Lung (risk assessment) and IQ Lung (treatment guidance), while a smaller segment provides testing and assay development for biopharma partners. The company’s value proposition is anchored in improving clinical decision-making and reducing unnecessary invasive procedures for lung cancer patients.

Performance Analysis

Biodesix’s Q2 results underscore a sharp operational turnaround in its core lung diagnostics segment, which now accounts for the overwhelming majority of revenue. Core lung diagnostics revenue reached $11.4 million, up 58% year-over-year, with test volumes up 75% to 9,800—both record highs. This surge was driven by robust adoption across community, rural, and academic pulmonology groups, with Notify Lung tests (Notify XL2 and Notify CDT) leading the charge. The company’s biopharma services segment remained subdued at $423,000, reflecting industry-wide delays in clinical trial enrollment and execution, though a $9.3 million backlog provides future visibility.

Gross margin expanded to 73%, a material improvement from the prior year and ahead of internal targets, fueled by the higher-margin lung diagnostics mix and workflow optimizations. Operating expenses were tightly controlled, declining sequentially, as management prioritized near-term revenue-generating projects over longer-term initiatives. Cash burn moderated, aided by cost discipline and the cessation of commercial COVID testing, while a $27.5 million insider-led private placement post-quarter-end bolstered liquidity and signaled internal conviction.

• Volume-Driven Leverage: Record test volumes enabled fixed-cost absorption and margin expansion, amplifying the impact of commercial execution.
• Services Volatility Persists: Biopharma services remain a drag, with revenue still well below prior-year levels despite strong backlog.
• Cost Structure Realignment: Operating expense reductions and project reprioritization are accelerating the timeline to profitability.

Overall, Biodesix’s financial and operational progress is tightly linked to lung diagnostics adoption, with biopharma services providing optionality but little near-term contribution.

Executive Commentary

Strategic Positioning

1. Commercial Execution in Lung Diagnostics

Biodesix has achieved commercial momentum in lung diagnostics, with broad adoption across physician segments and repeat ordering behavior strengthening. Sales team access to clinicians has normalized post-pandemic, and peer-to-peer education is increasing clinical comfort and repeat usage. The Oracle study’s publication, showing a 74% reduction in unnecessary invasive procedures with Notify XL2, further cements clinical utility and supports payer adoption.

2. Reimbursement and Clinical Evidence Flywheel

Reimbursement expansion is a core strategic lever, with three tests now holding Advanced Diagnostic Laboratory Test (ADLT) status from CMS, validating the uniqueness and clinical value of Biodesix’s offerings. Recent clinical data and independent studies reinforce the use case for payers and providers, driving a virtuous cycle of adoption and coverage.

3. Operational Discipline and Facility Investments

Management’s focus on cost discipline is evident in sequential operating expense reductions and project reprioritization. The imminent move to a new, energy-efficient facility will expand testing capacity, improve workflow, and support future volume growth, while also advancing ESG objectives. CapEx remains controlled, with tenant improvement dollars winding down and no step-up in out-of-pocket investment anticipated.

4. Biopharma Services: Latent Upside, Near-Term Drag

While biopharma services revenue remains muted due to industry-wide clinical trial delays, the $9.3 million contracted backlog and rising RFP activity signal pent-up demand. Management expects continued lumpiness but sees the segment as a potential growth lever as trial activity resumes.

Key Considerations

This quarter’s results reflect a business at an inflection point, with execution, reimbursement, and clinical utility converging to drive core revenue growth, but with ongoing biopharma volatility and capital allocation questions in focus.

Key Considerations:

• Lung Diagnostics Market Penetration: Record test volumes and broad physician adoption underscore the company’s first-mover advantage and growing clinical acceptance.
• Margin Structure and Cost Control: Sustained gross margin improvement and operating expense discipline are critical for the path to profitability.
• Reimbursement Expansion: Additional ADLT designations and positive clinical data enhance payer coverage and long-term revenue visibility.
• Biopharma Services Backlog: Contracted backlog provides latent upside, but near-term revenue realization remains uncertain amid trial delays.
• Insider-Led Capital Raise: The $27.5 million private placement by insiders signals internal confidence but also highlights ongoing capital needs.

Risks

Biodesix faces several risks, including ongoing biopharma services revenue volatility due to clinical trial enrollment delays, potential reimbursement headwinds as payer policies evolve, and the inherent execution risk in scaling commercial operations. Capital intensity remains a concern, with continued cash burn and upcoming CapEx for the new facility, though recent insider investment mitigates near-term liquidity risk. Finally, competitive dynamics in lung diagnostics could intensify as new entrants emerge or existing players expand their offerings.

Forward Outlook

For Q3 and Q4 2023, Biodesix management expects:

• Sequential step-ups in core lung diagnostics revenue and test volumes, mirroring 2022 seasonality.
• Continued gross margin in the low 70% range, inclusive of current biopharma contracts.

For full-year 2023, management maintained guidance:

• Revenue of $52 to $55 million, driven by strong lung diagnostics growth and modest biopharma services contribution.

Management emphasized sustained momentum in core testing, ongoing reimbursement expansion, and disciplined cost structure as key drivers for the remainder of the year.

• Biopharma services expected to remain lumpy, with backlog providing future optionality.
• Facility move and operational investments to support long-term scalability and efficiency.

Takeaways

Biodesix’s Q2 performance marks a clear inflection in commercial execution and financial discipline, with lung diagnostics adoption, margin expansion, and insider alignment driving positive momentum.

• Commercial Growth Engine: Core lung diagnostics is now the company’s growth engine, with adoption and volume trends supporting sustainable revenue expansion.
• Margin and Cost Focus: Accelerating margin improvement and expense control are compressing the timeline to profitability, even as biopharma services remain a drag.
• Future Watchpoint: Investors should monitor biopharma services backlog conversion, reimbursement policy evolution, and the ramp of the new facility for signs of further operational leverage or risk.

Conclusion

Biodesix delivered a breakout quarter in lung diagnostics, combining top-line growth with operational discipline and margin gains. While biopharma services remain a headwind, the company’s core business is scaling, and recent insider investment affirms management’s conviction in the long-term opportunity.

Industry Read-Through

Biodesix’s performance highlights the growing clinical and economic value of precision diagnostics in lung cancer, with payer coverage and clinical utility data emerging as key adoption drivers. Industry-wide clinical trial delays continue to impact biopharma services providers, suggesting that diagnostics companies with diversified revenue streams and strong core franchises are better positioned for near-term resilience. As reimbursement criteria tighten and competition intensifies, the ability to deliver robust clinical evidence and operational efficiency will differentiate winners in the diagnostics sector.

BDSX Healthcare Diagnostics Lung Cancer Precision Medicine Reimbursement Clinical Trials